Influence of hyperforin on the morphology of internal organs and biochemical parameters, in experimental model in mice.
OBJECTIVE
Hyperforin (HY) is used to treat depression and skin irritation and has been shown a number of pharmacological activities. The literature does no cite data on changes that may occur in the body after HY intake (ethylene diammonium salt - EDS) in long-term administration. From this point of view, the present work is a key to determining the pharmacotoxicological profile of the HY-EDS, in long-term administration.


METHODS
In present research, the influence of toxic doses of HY-EDS was investigated on the biochemical serum parameters and the histopathological changes in internal organs on the experimental mice model. For acute toxicity determination, the HY-EDS was tested in doses of 2000-5000 mg÷kg, administered once per day orally. For subacute toxicity, the HY-EDS was tested in three groups of mice, in doses of 50, 75 and 100 mg÷kg÷day, administered once daily, for 28 consecutive days.


CONCLUSIONS
As concern acute toxicity, a lethal effect has not occurred at any of the two tested doses and HY-EDS was classified as Class V toxic: median lethal dose (LD50) >5000 mg÷kg, p.o. After 14 days of follow-up in acute toxicity, the experimental results showed a statistically significant increase of aspartate transaminase (AST) and alanine transaminase (ALT), compared to the control group. There were no changes in creatinine and serum glucose compared to the control group. After the administration of repeated doses, it was observed an increase of serum transaminases and alkaline phosphatase. Histological examination revealed that the liver injuries were in an initial stage, making them reversible in case of HY-EDS treatment discontinuation. There was no evidence of kidney damage to any of the doses of HY-EDS.
Faculty of Pharmacy, University of Medicine and Pharmacy of Craiova, Romania; floriana_umf@yahoo.com.
Simona
S
Negreş
Corina
C
Scutari
Floriana Elvira
FE
Ionică
Veaceslav
V
Gonciar
Bruno Ştefan
BŞ
Velescu
Oana Cristina
OC
Şeremet
Anca
A
Zanfirescu
Cristina Elena
CE
Zbârcea
Emil
E
Ştefănescu
Emilia
E
Ciobotaru
Cornel
C
ChiriŢă
D000818:Animals; D015415:Biomarkers / Q000378:metabolism*; D001835:Body Weight / Q000187:drug effects; D001921:Brain / Q000187:drug effects / Q000473:pathology; D007668:Kidney / Q000187:drug effects / Q000473:pathology; D008099:Liver / Q000187:drug effects / Q000473:pathology; D008297:Male; D051379:Mice; D023421:Models, Animal; D009043:Motor Activity / Q000187:drug effects; D009928:Organ Specificity / Q000187:drug effects*; D010696:Phloroglucinol / Q000031:analogs & derivatives* / Q000737:chemistry / Q000633:toxicity; D013729:Terpenes / Q000737:chemistry / Q000633:toxicity*; D023382:Toxicity Tests, Acute
D015415:Biomarkers; D013729:Terpenes; D010696:Phloroglucinol; C001654:hyperforin